An open-label, single arm, phase II trial of niraparib maintenance treatment in patients with primary, platinum resistant ovarian cancer and Exploration of PARPi resistance mechanism
Latest Information Update: 01 Dec 2020
At a glance
- Drugs Niraparib (Primary)
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 01 Dec 2020 New trial record